Introduction
Molybdenum cofactor deficiency (MOCD) is a rare metabolic disorder with neurological symptoms of neonatal onset, developmental delay, seizures and motor abnormalities, first described in 1978 (1) . If undiagnosed, this disorder can result in rapid progressive encephalopathy and death. Early diagnosis is important in this lethal disorder as treatment with cyclic pyranopterin monophosphate (cPMP) could arrest the progression of MOCD type A (2).
We describe an infant with MOCD having early onset refractory seizures and imaging findings mimicked hypoxic-ischemic encephalopathy.
Restricted diffusion was noted along the corticospinal tract in our patient.
It is a novel imaging finding in patients with MOCD and a novel mutation
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Case report
A three-month-old boy born first in birth order to a non-consanguineously married Indian couple was referred for the evaluation of global developmental delay and refractory seizures. Informed consent was taken from the mother. Mother had no antenatal risk factors. The baby was delivered full term by normal vaginal delivery with a birth weight of 3200 g. Neonatal transition was uneventful.
Jaundice was noticed on third day of life and the maximum bilirubin recorded was 16.3 mg/dL. Diagnosis of MOCD was suspected based on the
Fig 1: MRI brain T2 axial (A) and FLAIR (B) images show bilateral parieto-occipital cystic encephalomalacia (red arrows) and deep white matter hyperintensities (black arrows). Volume loss and signal changes of caudate (blue arrow-single) and putamen (blue arrows-double) are seen in T2 axial (C) image. Corresponding T1 coronal image (D) shows hyperintense signal (blue arrows-single and double) which could represent early calcification. Also note the sparing of thalamus. MRS from parenchyma shows peak at TE 35 (E) with inversion at TE 144 (F) suggestive of lactate.
Fig 2: MRI brain T1 sagittal image (A) shows diffuse thinning of corpus callosum (white arrow); brainstem appear normal and cerebellum also appear normal (double arrows). DWI (B) and ADC (C) images show restricted diffusion along corticospinal tracts at the corona radiata (white arrows).
clinical, radiological findings and biochemical markers. MOCS1 and MOCS2 genes were with MOCD deficiency (8, 9) . Elevated lactate peak was observed in our patient as described in a previous report (2) . It could possibly be due to energy failure resulting from neurotoxic effect of sulfite on the mitochondria.
Three types of MOCD have been described based on the genetic defect that includes type 1 due to MOCS1 mutation, type 2 due to MOCS2 mutation and type 3 due to GEPHYRIN mutation. More research is needed to explore further treatment options in this otherwise lethal disorder.
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